JP2018500385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500385A5 JP2018500385A5 JP2017544555A JP2017544555A JP2018500385A5 JP 2018500385 A5 JP2018500385 A5 JP 2018500385A5 JP 2017544555 A JP2017544555 A JP 2017544555A JP 2017544555 A JP2017544555 A JP 2017544555A JP 2018500385 A5 JP2018500385 A5 JP 2018500385A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence identity
- pain
- conotoxin peptide
- item
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 108050003126 conotoxin Proteins 0.000 claims description 44
- 208000002193 Pain Diseases 0.000 claims description 30
- 230000036407 pain Effects 0.000 claims description 27
- 150000001413 amino acids Chemical group 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 230000004968 inflammatory condition Effects 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- JBZXBEBRZLKCGN-BYPYZUCNSA-N (2s)-2-(2-diazohydrazinyl)pentanoic acid Chemical compound CCC[C@@H](C(O)=O)NN=[N+]=[N-] JBZXBEBRZLKCGN-BYPYZUCNSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims description 2
- 201000007954 uterine fibroid Diseases 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 6
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 4
- 150000004665 fatty acids Chemical group 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091058551 α-conotoxin Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462123123P | 2014-11-07 | 2014-11-07 | |
| US62/123,123 | 2014-11-07 | ||
| PCT/US2015/059613 WO2016073949A1 (en) | 2014-11-07 | 2015-11-06 | Modifications and uses of conotoxin peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020040876A Division JP2020090550A (ja) | 2014-11-07 | 2020-03-10 | コノトキシンペプチドの修飾および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500385A JP2018500385A (ja) | 2018-01-11 |
| JP2018500385A5 true JP2018500385A5 (enExample) | 2018-12-13 |
| JP6798998B2 JP6798998B2 (ja) | 2020-12-09 |
Family
ID=55909927
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544555A Active JP6798998B2 (ja) | 2014-11-07 | 2015-11-06 | コノトキシンペプチドの修飾および使用 |
| JP2020040876A Withdrawn JP2020090550A (ja) | 2014-11-07 | 2020-03-10 | コノトキシンペプチドの修飾および使用 |
| JP2022010036A Pending JP2022063872A (ja) | 2014-11-07 | 2022-01-26 | コノトキシンペプチドの修飾および使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020040876A Withdrawn JP2020090550A (ja) | 2014-11-07 | 2020-03-10 | コノトキシンペプチドの修飾および使用 |
| JP2022010036A Pending JP2022063872A (ja) | 2014-11-07 | 2022-01-26 | コノトキシンペプチドの修飾および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11014970B2 (enExample) |
| EP (1) | EP3215172B1 (enExample) |
| JP (3) | JP6798998B2 (enExample) |
| KR (1) | KR102623475B1 (enExample) |
| CN (1) | CN107249616A (enExample) |
| AU (2) | AU2015342767B2 (enExample) |
| CA (1) | CA2966865C (enExample) |
| ES (1) | ES2950901T3 (enExample) |
| HK (1) | HK1244201A1 (enExample) |
| IL (2) | IL284236B2 (enExample) |
| TW (2) | TWI708790B (enExample) |
| WO (1) | WO2016073949A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI708790B (zh) | 2014-11-07 | 2020-11-01 | 美商奇尼塔慢性疼痛有限責任公司 | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 |
| RU2731217C2 (ru) * | 2016-11-28 | 2020-08-31 | Общество с ограниченной ответственностью "Синейро" | Аналог альфа-конотоксина RgIA для лечения боли |
| US10947274B1 (en) * | 2018-05-01 | 2021-03-16 | University Of Utah Research Foundation | Synthetic analgesic peptides of RgIA analogs |
| KR102117106B1 (ko) | 2018-09-14 | 2020-06-01 | 대한민국(환경부 국립생물자원관장) | N형 칼슘채널 차단 활성을 갖는 긴호랑거미 유래 알지신-ⅰ 펩타이드 및 이의 용도 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| AU2019418319B2 (en) * | 2019-01-04 | 2025-08-21 | Pacira Pharmaceuticals, Inc. | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| JP2023523899A (ja) * | 2020-04-09 | 2023-06-08 | ジーエルオー ファーマ，インク． | ニコチン性アセチルコリン受容体活性を阻害するためのペプチド組成物および方法 |
| KR20230031884A (ko) * | 2020-06-03 | 2023-03-07 | 유타대학연구재단 | 형태적으로 제약된 α-RGIA 유사체 |
| CN114805492B (zh) * | 2022-03-15 | 2025-07-22 | 上海元炘执药科技有限公司 | 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用 |
| CN115286700B (zh) * | 2022-08-22 | 2024-11-19 | 中国海洋大学 | 一种具有血浆稳定性的镇痛多肽 |
| CN118184744A (zh) * | 2024-03-29 | 2024-06-14 | 广西大学 | 一种靶向神经型乙酰胆碱受体的多肽分子及其制备方法和应用 |
| CN119912549A (zh) * | 2024-12-29 | 2025-05-02 | 中国人民解放军军事科学院防化研究院 | 一类脂肪醛修饰的芋螺肽及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595972A (en) | 1993-06-29 | 1997-01-21 | University Of Utah Research Foundation | Conotoxin peptides |
| US6797808B1 (en) | 1999-01-29 | 2004-09-28 | University Of Utah Research Foundation | α-conotoxin peptides |
| HUP0203504A3 (en) | 1999-10-18 | 2005-03-29 | Akzo Nobel Nv | Modified peptides and peptidomimetics for use in immunotherapy |
| EP1578787B1 (en) | 2002-12-02 | 2012-11-14 | Xenome Ltd | Novel chi-conotoxin peptides (-ii) |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| EP1770099A1 (en) * | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| US7745573B2 (en) | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| CA2566832A1 (en) * | 2006-04-13 | 2007-10-13 | The University Of Queensland | Cyclised alpha-conotoxin peptides |
| US9284358B2 (en) * | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| EP2310407A4 (en) | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES |
| DE102009050885A1 (de) * | 2009-10-27 | 2011-04-28 | Behr Gmbh & Co. Kg | Luftausströmer |
| WO2014194284A1 (en) | 2013-05-31 | 2014-12-04 | Mcintosh J Michael | Conotoxin peptides, pharmaceutical compositions and uses thereof |
| TWI708790B (zh) | 2014-11-07 | 2020-11-01 | 美商奇尼塔慢性疼痛有限責任公司 | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
-
2015
- 2015-11-06 TW TW104136722A patent/TWI708790B/zh not_active IP Right Cessation
- 2015-11-06 EP EP15856496.3A patent/EP3215172B1/en active Active
- 2015-11-06 CN CN201580068468.7A patent/CN107249616A/zh active Pending
- 2015-11-06 US US15/525,024 patent/US11014970B2/en active Active
- 2015-11-06 JP JP2017544555A patent/JP6798998B2/ja active Active
- 2015-11-06 CA CA2966865A patent/CA2966865C/en active Active
- 2015-11-06 HK HK18103429.5A patent/HK1244201A1/zh unknown
- 2015-11-06 AU AU2015342767A patent/AU2015342767B2/en active Active
- 2015-11-06 IL IL284236A patent/IL284236B2/en unknown
- 2015-11-06 WO PCT/US2015/059613 patent/WO2016073949A1/en not_active Ceased
- 2015-11-06 TW TW109134130A patent/TWI777260B/zh not_active IP Right Cessation
- 2015-11-06 KR KR1020177015279A patent/KR102623475B1/ko active Active
- 2015-11-06 ES ES15856496T patent/ES2950901T3/es active Active
-
2017
- 2017-05-07 IL IL252152A patent/IL252152B/en unknown
-
2020
- 2020-03-10 JP JP2020040876A patent/JP2020090550A/ja not_active Withdrawn
- 2020-09-29 US US17/037,521 patent/US11618772B2/en active Active
-
2021
- 2021-08-03 AU AU2021212006A patent/AU2021212006B2/en active Active
-
2022
- 2022-01-26 JP JP2022010036A patent/JP2022063872A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500385A5 (enExample) | ||
| TWI708790B (zh) | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 | |
| JP2011511753A5 (enExample) | ||
| TW202140513A (zh) | 人類運鐵蛋白受體結合肽 | |
| JP2022551153A (ja) | 活性ポリペプチド化合物 | |
| US20240139279A1 (en) | Cyclic prosaposin peptides and uses thereof | |
| JP2023512587A (ja) | Ｐａｎｘ１関連疾患の治療 | |
| US20170246311A1 (en) | Peptides for binding alternatively activated macrophages | |
| EP2909226A1 (en) | Derivatives of collagen-binding hairpin peptides | |
| JP6615504B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| CA2581110A1 (en) | Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions | |
| JP2005060315A (ja) | 製剤組成物 | |
| ES3040184T3 (en) | Fusion protein preparation comprising il-2 and cd80 proteins | |
| JP6831128B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| RU2021115678A (ru) | Конъюгаты интерлейкина 10 и варианты их применения | |
| HK40090948A (en) | Cyclic prosaposin peptides and uses thereof | |
| Huang | Biomimicry: Exploring Peptoids and Recombinant Protein Polymers for Biomedical Applications | |
| NZ741870B2 (en) | Integrin binding peptides and uses thereof | |
| HK1233930A1 (en) | Cyclic prosaposin peptides and uses thereof | |
| HK1233930B (en) | Cyclic prosaposin peptides and uses thereof | |
| NZ741870A (en) | Integrin binding peptides and uses thereof |